NASDAQ:ITOS

iTeos Therapeutics Competitors

$27.01
-2.99 (-9.97 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.70
Now: $27.01
$29.99
50-Day Range
$30.00
MA: $37.18
$44.20
52-Week Range
$17.50
Now: $27.01
$47.61
Volume507,400 shs
Average Volume281,797 shs
Market Capitalization$948.02 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

iTeos Therapeutics (NASDAQ:ITOS) Vs. SEER, NUVB, IBRX, BCAB, IMCR, and CGEM

Should you be buying ITOS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to iTeos Therapeutics, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), and Cullinan Oncology (CGEM).

iTeos Therapeutics (NASDAQ:ITOS) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iTeos Therapeutics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
SeerN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Seer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
Seer02202.50

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Seer has a consensus price target of $68.00, indicating a potential upside of 30.79%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Seer.

Valuation and Earnings

This table compares iTeos Therapeutics and Seer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Summary

iTeos Therapeutics beats Seer on 4 of the 4 factors compared between the two stocks.

iTeos Therapeutics (NASDAQ:ITOS) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iTeos Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
Nuvation BioN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
Nuvation Bio00603.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 74.00%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares iTeos Therapeutics and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

iTeos Therapeutics beats Nuvation Bio on 2 of the 3 factors compared between the two stocks.

iTeos Therapeutics (NASDAQ:ITOS) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iTeos Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
ImmunityBioN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
ImmunityBio00103.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 48.19%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than ImmunityBio.

Valuation and Earnings

This table compares iTeos Therapeutics and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

iTeos Therapeutics beats ImmunityBio on 3 of the 3 factors compared between the two stocks.

iTeos Therapeutics (NASDAQ:ITOS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iTeos Therapeutics and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
BioAtlaN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
BioAtla00403.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 22.49%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares iTeos Therapeutics and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Summary

iTeos Therapeutics beats BioAtla on 3 of the 3 factors compared between the two stocks.

iTeos Therapeutics (NASDAQ:ITOS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares iTeos Therapeutics and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
ImmunocoreN/AN/AN/A

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares iTeos Therapeutics and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Immunocore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
Immunocore01202.67

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 53.18%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Immunocore.

Summary

iTeos Therapeutics beats Immunocore on 4 of the 4 factors compared between the two stocks.

iTeos Therapeutics (NASDAQ:ITOS) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares iTeos Therapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iTeos TherapeuticsN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Insider & Institutional Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares iTeos Therapeutics and Cullinan Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iTeos TherapeuticsN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for iTeos Therapeutics and Cullinan Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iTeos Therapeutics00503.00
Cullinan Oncology01302.75

iTeos Therapeutics currently has a consensus target price of $49.40, indicating a potential upside of 82.90%. Cullinan Oncology has a consensus target price of $48.25, indicating a potential upside of 49.38%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe iTeos Therapeutics is more favorable than Cullinan Oncology.

Summary

iTeos Therapeutics beats Cullinan Oncology on 4 of the 4 factors compared between the two stocks.


iTeos Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$51.99-3.2%$3.17 billionN/A0.00
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00-0.2%$2.18 billionN/A0.00High Trading Volume
IBRX
ImmunityBio
1.7$16.87-10.8%$1.84 billionN/A0.00Analyst Revision
BioAtla logo
BCAB
BioAtla
1.5$47.35-0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47-2.3%$1.53 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30-5.8%$1.41 billionN/A0.00
EWTX
Cricut
0.3$29.54-1.6%$1.41 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$31.55-0.5%$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07-5.4%$1.33 billionN/A0.00Analyst Revision
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12-9.2%$1.29 billionN/A0.00
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02-5.2%$1.19 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00
PHAR
Pharming Group
0.0$13.26-1.1%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Revision
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00News Coverage
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Revision
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.44-2.2%$557.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48-1.4%$456.41 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13-4.7%$432.21 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Revision
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54-0.8%$262.47 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00Gap Up
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00News Coverage
Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
Gap Up
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.